{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:38:07Z","timestamp":1794541087225,"version":"4.9.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to investigate the clinical characteristics of patients with difficult-to-treat RA (D2T RA) and the usefulness of switching to drugs with different modes of action in real-world.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed all consecutive patients with RA treated at Keio University Hospital between 2016 and 2017 with a definition of D2T RA. We analysed clinical characteristics and evaluated the usefulness of changing drugs according to mode of action.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 1709 patients with RA, 173 (10.1%) were D2T RA. The reason for the D2T RA was multi-drug resistance in 59 patients (34.1%), comorbidity in 17 (9.8%), and socio-economic reasons in 97 (56.1%). The multi-drug-resistance group had significantly higher tender joint count and evaluator global assessment than the other groups, despite receiving the most intensive treatment. The comorbidity group showed a significantly older age and higher rheumatic disease comorbidity index. Although changing the drug to another with a different mode of action was useful, the proportion of patients who achieved remission or low disease activity decreased as the number of switches increased.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Of the patients with RA, 10.1% were still difficult to treat in clinical practice, despite intensive treatment. Their characteristics were distinct by the reasons of D2T RA, which suggests the need for a personalized approach to D2T RA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab209","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T12:33:00Z","timestamp":1614601980000},"page":"5247-5256","source":"Crossref","is-referenced-by-count":92,"title":["Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3607-2140","authenticated-orcid":false,"given":"Satoshi","family":"Takanashi","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"2021110402575590800_keab209-B1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/annrheumdis-2019-216607","article-title":"CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice","volume":"79","author":"Takanashi","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B3","first-page":"1135","article-title":"Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need","volume":"57","author":"de Hair","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2021110402575590800_keab209-B4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","article-title":"Risk profiling for a refractory course of rheumatoid arthritis","volume":"49","author":"B\u00e9c\u00e8de","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2021110402575590800_keab209-B5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","article-title":"Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Kearsley-Fleet","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2021110402575590800_keab209-B8","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.22456","article-title":"Validation of the rheumatic disease comorbidity index","volume":"67","author":"England","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021110402575590800_keab209-B10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2021110402575590800_keab209-B11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/acr.23873","article-title":"Sex differences in the achievement of remission and low disease activity in rheumatoid arthritis","volume":"72","author":"Maynard","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021110402575590800_keab209-B12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/ard.2010.139212","article-title":"Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial","volume":"70","author":"Saevarsdottir","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B13","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/ard.2007.084897","article-title":"Sex: a major predictor of remission as measured by 28-joint Disease Activity Score (DAS28) in early rheumatoid arthritis?","volume":"67","author":"M\u00e4kinen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B14","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/annrheumdis-2018-214918","article-title":"Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis","volume":"78","author":"Aletaha","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/ard.2005.038513","article-title":"Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials","volume":"65","author":"Aletaha","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/1756-185X.13428","article-title":"Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort","volume":"22","author":"Murata","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2021110402575590800_keab209-B17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13075-017-1401-2","article-title":"High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study","volume":"19","author":"Takeuchi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2021110402575590800_keab209-B19","doi-asserted-by":"crossref","first-page":"102405","DOI":"10.1016\/j.jaut.2020.102405","article-title":"Precision medicine and management of rheumatoid arthritis","volume":"110","author":"Aletaha","year":"2020","journal-title":"J Autoimmun"},{"key":"2021110402575590800_keab209-B20","first-page":"1234","article-title":"Shared epitope positivity is related to the efficacy of abatacept in rheumatoid arthritis","volume":"77","author":"Oryoji","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13075-020-2137-y","article-title":"Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis","volume":"22","author":"Yokoyama-Kokuryo","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2021110402575590800_keab209-B22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-016-1052-8","article-title":"Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study","volume":"18","author":"Nakamura","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021110402575590800_keab209-B23","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.38671","article-title":"Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial","volume":"66","author":"Sellam","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021110402575590800_keab209-B24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.40810","article-title":"Profiling of gene expression biomarkers as a classifier of methotrexate nonresponse in patients with rheumatoid arthritis","volume":"71","author":"Plant","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021110402575590800_keab209-B25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13075-017-1387-9","article-title":"A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study","volume":"19","author":"Nakagawa","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2021110402575590800_keab209-B26","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II Trial (ANDES Study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2021110402575590800_keab209-B27","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/annrheumdis-2013-204816","article-title":"MOR103, a human monoclonal antibody to granulocyte\u2013macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib\/IIa randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"74","author":"Behrens","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clinthera.2017.11.011","article-title":"Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients with Rheumatoid Arthritis","volume":"40","author":"Gossage","year":"2018","journal-title":"Clin Ther"},{"key":"2021110402575590800_keab209-B29","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","article-title":"Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis","volume":"52","author":"Ranganath","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2021110402575590800_keab209-B30","first-page":"914","article-title":"Similar efficacy, safety, and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study","volume":"77","author":"Cohen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021110402575590800_keab209-B31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2017-211741","article-title":"Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab209\/39733648\/keab209.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5247\/41073256\/keab209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5247\/41073256\/keab209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T03:00:44Z","timestamp":1635994844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/11\/5247\/6158040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,3,3]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab209","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,3,3]]}}}